Necroptosis Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Necroptosis is a programmed form of cell death characterized by cellular swelling, membrane rupture, and release of intracellular contents. Unlike apoptosis, necroptosis is inherently pro-inflammatory due to the release of damage-associated molecular patterns (DAMPs). Mounting evidence implicates necroptosis in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. This pathway examines the molecular mechanisms of necroptosis and its contribution to neurodegeneration.
The necroptosis pathway centers on three key proteins:
Necroptosis can be initiated by:
{{mermaid}}
flowchart TD
A[TNF-α] --> B[TNFR1]
B --> C[RIPK1 Activation]
D[FasL] --> E[Fas/CD95]
E --> C
F[TLR3/TLR4] --> G[TRIF]
G --> C
H[ZBP1/DAI] --> I[RIPK3 Activation]
C --> J{RIPK1 Ubiquitination?}
J -->|Yes| K[NF-κB Survival Pathway]
J -->|No| I
I --> L[RIPK3 Recruitment]
L --> M[MLKL Phosphorylation]
M --> N[MLKL Oligomerization]
N --> O[Membrane Translocation]
O --> P[Cell Lysis]
P --> Q[DAMPs Release]
Q --> R[Inflammation]
{{/mermaid}}
Amyloid-Beta Relationship
Tau Pathology
| Target | Drug | Status |
|---|---|---|
| RIPK1 | Necrostatin-1 | Preclinical |
| RIPK1 | GSK'963 | Phase 1 |
| RIPK1 | DNL747 | Discontinued |
| RIPK3 | HBSP1 | Preclinical |
| Compound | Target | IC50 | Development |
|---|---|---|---|
| Necrostatin-1 | RIPK1 | 100 nM | Research tool |
| GSK'963 | RIPK1 | 1.8 nM | Phase 1 |
| Z-VAD-FMK | Caspases | 40 nM | Research tool |
| Ponatinib | Multiple kinases | Various | Approved for CML |
The study of Necroptosis Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Degterev A, Hitomi J, Germscheid M, et al. Identification of RIPK1 as a specific executor of necroptosis. Nat Chem Biol. 2008;4(5):313-321. PMID:18414490
Ofengeim D, Ito Y, Najafov A, et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 2015;10(11):1836-1849. PMID:25800952
Caccamo A, Branca C, Piras IS, et al. Necroptosis activation in Alzheimer's disease. Nat Neurosci. 2017;20(9):1236-1246. PMID:28714961
Ito Y, Ofengeim D, Najafov A, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353(6299):603-608. PMID:27493188
Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1 in the brain. Nat Rev Neurosci. 2019;20(12):735-748. PMID:31686019
Galluzzi L, Kepp O, Chan FK, Kroemer G. Necroptosis: mechanisms and relevance to disease. Annu Rev Pathol. 2017;12:103-130. PMID:27959630
Conrad M, Angeli JP, Vandenabeele P, et al. Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov. 2016;15(5):348-366. PMID:26775689
Weinlich R, Oberst A, Beere HM, Green DR. Necroptosis in development, inflammation and disease. Nat Rev Mol Cell Biol. 2017;18(2):127-136. PMID:27999438
Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1-2):213-227. PMID:22265413
Zhao J, Jitkaew S, Cai Z, et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci U S A. 2012;109(14):5322-5327. PMID:22421439
Pasparakis M, Vandenabeele P. Necroptosis and its role in disease. Nature. 2015;517(7534):311-320. PMID:25607648
Vitner EB, Salomon R, Farfel M, et al. RIPK3 as a potential therapeutic target for neurodegenerative diseases. Nat Rev Neurol. 2014;10(7):402-410. PMID:24980147
Liu Y, Fan Y, Wang Y, et al. Necroptosis: a novel therapeutic target for Parkinson's disease. Neural Regen Res. 2023;18(4):747-754. PMID:36204836
Rodriguez M, Rodriguez-Sabate C, Rodriguez I, et al. Necroptosis in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:219-227. PMID:30690151
Hanson B, Tulkki VA, Terman A, et al. Necroptosis in neurodegenerative disease. J Mol Biol. 2022;434(4):167218. PMID:34742750
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 50% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 49%